Skip to main content
Photo header of senior man
Photo header of senior man
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior man header
Photo header of senior man
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
March 4, 2025

Patient Matters Video Series: Knowledge is Power

In the latest installment of our Patient Matters video series, Daryn Kagan talks with Bill…
Insights
January 28, 2025

A Victory in The Battle for Parkinson’s Disease Prevention

In December 2024, the U.S. Environmental Protection Agency (EPA) announced a plan to limit and…
Insights
December 13, 2024

The Skin May Offer Clues About Parkinson’s Disease and Its Progression Over Time

CND Life Sciences is conducting a clinical research study to learn more about the progression…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

On Our Radar
June 23, 2025

Pesticides Near Golf Courses Associated with Increased Risk of Parkinson’s Disease

Parkinson’s disease is complex, involving both genetic and environmental factors, including air pollution and other chemical exposures. In particular, pesticide exposure has been…
CND In the News
June 17, 2025

Healio Covers Research on the Syn-One Test’s Role for People with REM Sleep Behavior Disorder

Healio covered recent research showing how CND Life Sciences’ Syn-One Test® detects a key neurodegenerative…
News Release
June 5, 2025

CND Life Sciences’ Syn-One Test® Detects Alpha-Synuclein in Skin Biopsies of Patients with REM Sleep Behavior Disorder

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our Skin Biopsy Test Kit, collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit